Cilostazol has 20 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 8 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Anagrelide, Anagrelide Hydrochloride, Cladribine. Patients taking Cilostazol should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Contraindicated
- 1
- Major
- 8
- Moderate
- 10
Contraindicated (1)
- Cilostazol + Anagrelide— Avoid use; both are PDE3 inhibitors with exacerbation of inotropic effects.
Major (8)
- Cilostazol + Anagrelide Hydrochloride— Avoid use due to exacerbation of inotropic effects as PDE3 inhibitor.
- Cilostazol + Cladribine— Potent BCRP, ENT1, and CNT3 transporter inhibitor may alter cladribine bioavailability, intracellular distribution, and …
- Cilostazol + Diltiazem— Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.
- Cilostazol + Erythromycin— Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.
- Cilostazol + Grapefruit Juice— Moderate CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.
- Cilostazol + Ketoconazole— Strong CYP3A4 inhibitor increases cilostazol exposure. Requires cilostazol dose reduction to 50 mg twice daily.
- Cilostazol + Omeprazole— CYP2C19 inhibitor increases systemic exposure of cilostazol active metabolites. Requires cilostazol dose reduction to 50…
- Cilostazol + Warfarin Sodium— CYP3A4 inhibitor that increases warfarin effect and INR; requires close monitoring.
Moderate (10)
- Cilostazol + Esomeprazole— CYP2C19 substrate; potential for interaction with esomeprazole.
- Cilostazol + Esomeprazole Magnesium— CYP2C19 substrate; concomitant use with esomeprazole may alter exposure due to CYP2C19 inhibition.
- Cilostazol + Esomeprazole Magnesium Delayed Release Capsules— Esomeprazole magnesium may increase systemic exposure of cilostazol and its active metabolite. Consider dose reduction.
- Cilostazol + Esomeprazole Sodium— CYP2C19 substrate that may have altered exposure when used concomitantly with esomeprazole.
- Cilostazol + Methylergonovine— Weak CYP 3A4 inhibitor; should be administered with caution.
- Cilostazol + Methylergonovine Maleate— Weak CYP 3A4 inhibitor; should be administered with caution due to potential vasospasm risk.
- Cilostazol + Omeprazole And Sodium Bicarbonate— CYP2C19 substrate; concomitant use with omeprazole may increase exposure due to inhibition of CYP2C19.
- Cilostazol + Omeprazole Magnesium— CYP2C19 substrate; concomitant use with omeprazole may alter cilostazol concentrations.
- Cilostazol + Omeprazole Magnesium, Amoxicillin And Rifabutin— CYP2C19 substrate with increased plasma concentrations when combined with omeprazole.
- Cilostazol + Vonoprazan Fumarate— Vonoprazan is a CYP2C19 inhibitor and may increase exposure of cilostazol; monitor for adverse reactions.